Evidence map›Paper›PMID 26169757›Full record

ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2015

LPA signaling is required for dopaminergic neuron development and is reduced through low expression of the LPA1 receptor in a 6-OHDA lesion model of Parkinson's disease.

Xiao-Yun Yang, Ethan Y Zhao, Wen-Xin Zhuang, Feng-Xiang Sun, Hai-Lin Han, Hui-Rong Han, Zhi-Juan Lin, Zhi-Fang Pan, Mei-Hua Qu, Xian-Wei Zeng and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Xiao-Yun YangKey Lab of Applied Pharmacology, Wei Fang Medical College, Weifang, 261053, China.
Ethan Y ZhaoDepartment of Neurological Surgery, Wayne State University, Detroit, MI, USA. ezhao@med.wayne.edu.
Wen-Xin ZhuangKey Lab of Applied Pharmacology, Wei Fang Medical College, Weifang, 261053, China.
Feng-Xiang SunDepartment of Biochemistry, Wei Fang Medical College, Weifang, 261053, China.
Hai-Lin HanKey Lab of Applied Pharmacology, Wei Fang Medical College, Weifang, 261053, China.
Hui-Rong HanKey Lab of Applied Pharmacology, Wei Fang Medical College, Weifang, 261053, China.
Zhi-Juan LinDepartment of Immunology, Wei Fang Medical College, Weifang, 261053, China.
Zhi-Fang PanKey Lab of Applied Pharmacology, Wei Fang Medical College, Weifang, 261053, China.
Mei-Hua QuKey Lab of Applied Pharmacology, Wei Fang Medical College, Weifang, 261053, China. qumeihua@hotmail.com.
Xian-Wei ZengDepartment of Neurosurgery, The Affiliated Hospital of Wei Fang Medical College, Weifang, 261031, Shandong, China. ezhao@med.wayne.edu.
Yuchuan DingDepartment of Neurological Surgery, Wayne State University, Detroit, MI, USA.
Weifang Medical University · CNNeurological Surgery · USWayne State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lysophosphatidic acid (LPA) is a bioactive phospholipid that activates at least five known G-protein-coupled receptors (GPCRs): LPA1-LPA5. The nervous system is a major locus for LPA1 expression. LPA has been shown to regulate neuronal proliferation, migration, and differentiation during central nervous system development as well as neuronal survival. Furthermore, deficient LPA signaling has been implicated in several neurological disorders including neuropathic pain and schizophrenia. Parkinson's disease (PD) is a neurodegenerative movement disorder that results from the loss of dopaminergic (DA) neurons in the substantia nigra pars compacta (SNc). The specific molecular pathways that lead to DA neuron degeneration, however, are poorly understood. The influence of LPA in the differentiation of mesenchymal stem cells (MSCs) into DA neurons in vitro and LPA1 expression in a 6-hydroxydopamine (6-OHDA) lesion model of PD in vivo were examined in the present study. LPA induced neuronal differentiation in 80.2 % of the MSC population. These MSCs developed characteristic neuronal morphology and expressed the neuronal marker, neuron-specific enolase (NSE), while expression of the glial marker, glial fibrillary acidic protein (GFAP), was absent. Moreover, 27.6 % of differentiated MSCs were positive for tyrosine hydroxylase (TH), a marker for DA neurons. In the 6-OHDA PD rat model, LPA1 expression in the substantia nigra was significantly reduced compared to control. These results suggest LPA signaling via activation of LPA1 may be necessary for DA neuron development and survival. Furthermore, reduced LPA/LPA1 signaling may be involved in DA neuron degeneration thus contributing to the pathogenesis of PD.

Indexed as

AnimalsCell SurvivalCentral Nervous System AgentsDopaminergic NeuronsFemaleGlial Fibrillary Acidic ProteinLysophospholipidsMaleMesenchymal Stem CellsMyenteric PlexusNeurogenesisOxidopamineParkinsonian DisordersPhosphopyruvate HydrataseRats, Sprague-DawleyReceptors, Lysophosphatidic AcidCentral Nervous System AgentsGlial Fibrillary Acidic Proteinlysophosphatidic acidLysophospholipidsOxidopaminePhosphopyruvate HydrataseReceptors, Lysophosphatidic AcidTyrosine 3-MonooxygenaseDopaminergic (DA)G protein-coupled receptors (GPCRs)Lysophosphatidic acid receptor 1 (LPA1)Parkinson’s disease (PD)

Identifiers

PMID26169757
OpenAlexW903095732

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.